Purchase this article with an account.
M. Kusano, M. Uematsu, K. Shimoda, M. Teshima, T. Kumagami, H. Sasaki, T. Kitaoka; Additives Can Lessen Acute Corneal Epithelial Disorder Induced by Xalatan®. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4612.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate acute corneal epithelial disorders induced by the antiglaucomatous prostaglandin analogues Xalatan®, containing 0.02% benzalkonium chloride (BAC); Travatan®, containing 0.015% BAC; Travatanz®, without BAC; and, Travatan® additives. A second aim was to determine whether additives included in ophthalmic drugs can lessen the extent of acute corneal epithelial disorders induced by Xalatan®.
The corneal transepithelial electric resistance (TER) of live rabbits was measured before and after 60 seconds of exposure to Xalatan®, Travatan®, Travatanz®, and Travatan® additives. Cultured normal rabbit corneal epithelial (NRCE) cells were also exposed to the same drugs for 60 seconds and cell viability was evaluated using a WST-1 assay. Finally, the Travatan® additive, 1% polyoxyethylene hydrogenated castor oil (HCO), was mixed with 0.02% BAC and Xalatan®, and changes in TER, cell viability, and scanning electron microscopy (SEM) were examined.
Xalatan® significantly lowered TER (P < 0.0001) and NRCE viability (P < 0.0001), whereas Travatan® and Travatanz® did not significantly differ compared with the control. However, the mixture of 1% HCO, 0.02% BAC and Xalatan® did not significantly alter TER and cell viability compared with the control, and SEM did not detect any damage to the corneal epithelial superficial cells.
The inclusion of 1% HCO can lessen the extent of acute corneal epithelial disorder caused by 0.02% BAC and Xalatan®.
This PDF is available to Subscribers Only